文献速递血管炎

利妥昔单抗与环磷酰胺治疗危及生命的ANCA相关性血管炎的短期有效性与安全性:基于全国真实世界数据库的倾向性评分分析

Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database.
PubMed 文献 · Ann Rheum Dis · 2024-01-02

本研究利用日本全国住院数据库(2018年4月至2020年3月),纳入687例接受全身糖皮质激素联合利妥昔单抗(RTX)或静脉环磷酰胺(IVCY)治疗的危及生命ANCA相关性血管炎(AAV)患者,采用倾向性评分调整的Cox和logistic回归分析。结果显示两组院内死亡率无显著差异(校正HR 1.06;95%CI 0.62-1.80),RTX组真菌感染(aOR 0.45;95%CI 0.23-0.84)和肺孢子菌肺炎(aOR 0.58;95%CI 0.32-1.00)风险较低,但出院时需血液透析的严重肾功能不全风险可能升高(aOR 2.58;95%CI 1.02-6.91)。

要点

  • 危及生命AAV中RTX与IVCY的院内死亡率无显著差异(校正HR 1.06;95%CI 0.62-1.80)。
  • RTX组真菌感染风险较低(aOR 0.45;95%CI 0.23-0.84),肺孢子菌肺炎风险也可能较低(aOR 0.58;95%CI 0.32-1.00)。
  • RTX组出院时需血液透析的严重肾功能不全风险可能升高(aOR 2.58;95%CI 1.02-6.91)。

核心结论

  • 在危及生命AAV中,RTX对死亡率的短期有效性与IVCY相似。
  • RTX的真菌感染和肺孢子菌肺炎风险可能较低,但短期肾脏预后可能劣于IVCY。

研究设计与样本

  • 研究利用日本全国住院数据库,提取2018年4月至2020年3月期间接受全身糖皮质激素联合RTX或IVCY治疗的危及生命AAV病例。
  • 从16 001 612条住院记录中提取687例危及生命AAV病例,采用倾向性评分调整的多变量Cox和logistic回归分析。

主要发现

  • 两组院内死亡率无显著差异(校正HR 1.06;95%CI 0.62-1.80)。
  • RTX组真菌感染风险较低(aOR 0.45;95%CI 0.23-0.84),肺孢子菌肺炎风险也可能较低(aOR 0.58;95%CI 0.32-1.00)。
  • RTX组出院时需血液透析的严重肾功能不全风险可能升高(aOR 2.58;95%CI 1.02-6.91)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Life-threatening antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) with rapidly progressive glomerulonephritis (RPGN) and/or alveolar haemorrhage (AH) has a poor prognosis. Rituximab (RTX) is as effective as cyclophosphamide (CY) in remission induction therapy; however, the effectiveness and safety of RTX have not been established in life-threatening AAV. This study aimed to investigate the short-term effectiveness and safety of RTX in life-threatening AAV with RPGN and/or AH. METHODS: Between April 2018 and March 2020, cases treated with systemic glucocorticoids and RTX or intravenous CY (IVCY) was extracted from a Japanese nationwide inpatient database. Effectiveness was evaluated by in-hospital mortality and severe renal dysfunction requiring haemodialysis (HD) at discharge. Safety was evaluated by the in-hospital incidence of infections. The propensity score (PS) for RTX was estimated. Multivariable Cox and logistic regression with adjustment for PS were conducted to estimate the association of RTX with outcomes. RESULTS: From 16 001 612 hospitalised records, 687 life-threatening AAV cases were extracted. No significant difference in in-hospital mortality (adjusted HR 1.06; 95% CI 0.62 to 1.80) was found between the groups. Although the RTX group had a lower risk of fungal infections (adjusted OR (aOR) 0.45; 95% CI 0.23 to 0.84) and pneumocystis pneumonia (aOR 0.58; 95% CI 0.32 to 1.00), they might have an increased risk of severe renal dysfunction requiring HD at discharge (aOR 2.58; 95% CI 1.02 to 6.91). CONCLUSIONS: In life-threatening AAV, RTX has similar short-term effectiveness on mortality to IVCY. Although RTX might have a lower risk of fungal infections and pneumocystis pneumonia, the short-term renal prognosis might be inferior to IVCY.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Ishikawa Y, Tokutsu K, Nakayamada S, et al. Short-term effectiveness and safety of rituximab versus cyclophosphamide for life-threatening ANCA-associated vasculitis: a propensity score analysis of the real-world nationwide database. Ann Rheum Dis. 2024. PMID: 37726117. doi:10.1136/ard-2023-224472

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。